(This story is for CNBC PRO subscribers only.)
Here are the biggest calls on Wall Street on Monday:
Atlantic Equities said in its downgrade of the stock that it sees "limited upside" after the company's second major trial of its early breast cancer drug "failed to show a benefit."
"With the failure of Ibrance in all early breast cancer indications now complete, we no longer see a path to above industry growth for PFE Biopharma. Also, with shares having rallied 15% off the late-June low, we see more limited upside at the current valuation based on our revised sum-of-the-parts $39 price target. We downgrade to Neutral."
Citi said in its downgrade of the stock that it's "less confident" in the company's ability to gain share or return to growth especially in markets that are declining.
"Cisco's switching and routing sales (~40% of sales) remain on the decline and we are less confident in the company's ability to return to growth or gain share, particularly in declining markets. As a result, we do not expect Cisco's hardware segment (Infrastructure Platforms) to return to growth near term."